Maze therapeutics announces pricing of upsized initial public offering

South san francisco, calif., jan. 30, 2025 (globe newswire) -- maze therapeutics, inc. (nasdaq: maze), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, today announced the pricing of its upsized initial public offering of 8,750,000 shares of its common stock at a public offering price of $16.00 per share. the gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $140.0 million. all shares of common stock to be sold in the offering will be sold by maze therapeutics. in addition, maze therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,312,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions. the shares are expected to begin trading on the nasdaq global market on january 31, 2025, under the symbol “maze.” the offering is expected to close on february 3, 2025, subject to the satisfaction of customary closing conditions.
MAZE Ratings Summary
MAZE Quant Ranking